AU2003294499A8 - Rhebs as modifiers of the rb pathway and methods of use - Google Patents

Rhebs as modifiers of the rb pathway and methods of use

Info

Publication number
AU2003294499A8
AU2003294499A8 AU2003294499A AU2003294499A AU2003294499A8 AU 2003294499 A8 AU2003294499 A8 AU 2003294499A8 AU 2003294499 A AU2003294499 A AU 2003294499A AU 2003294499 A AU2003294499 A AU 2003294499A AU 2003294499 A8 AU2003294499 A8 AU 2003294499A8
Authority
AU
Australia
Prior art keywords
rhebs
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2003294499A
Other versions
AU2003294499A1 (en
Inventor
Lynn Margaret Bjerke
Albert K Tai
Chunyan Song
Lucile A Gillett
Michael Martin Ollmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2003294499A1 publication Critical patent/AU2003294499A1/en
Publication of AU2003294499A8 publication Critical patent/AU2003294499A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003294499A 2002-11-25 2003-11-24 Rhebs as modifiers of the rb pathway and methods of use Abandoned AU2003294499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42887202P 2002-11-25 2002-11-25
US60/428,872 2002-11-25
PCT/US2003/037538 WO2004048536A2 (en) 2002-11-25 2003-11-24 Rhebs as modifiers of the rb pathway and methods of use

Publications (2)

Publication Number Publication Date
AU2003294499A1 AU2003294499A1 (en) 2004-06-18
AU2003294499A8 true AU2003294499A8 (en) 2004-06-18

Family

ID=32393472

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003294499A Abandoned AU2003294499A1 (en) 2002-11-25 2003-11-24 Rhebs as modifiers of the rb pathway and methods of use
AU2003294501A Ceased AU2003294501B2 (en) 2002-11-25 2003-11-24 CCT6S as modifiers of the RB pathway and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003294501A Ceased AU2003294501B2 (en) 2002-11-25 2003-11-24 CCT6S as modifiers of the RB pathway and methods of use

Country Status (5)

Country Link
EP (1) EP1578945A4 (en)
JP (1) JP4646631B2 (en)
AU (2) AU2003294499A1 (en)
CA (1) CA2506686A1 (en)
WO (2) WO2004048536A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133904A1 (en) 2007-04-23 2008-11-06 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
GB9608937D0 (en) * 1996-04-29 1996-07-03 Cancer Res Campaign Tech Screening methods for therapeutics and peptides used in the screen
EP1054969A2 (en) * 1998-02-12 2000-11-29 Curagen Corporation Retinoblastoma protein complexes and retinoblastoma interacting proteins

Also Published As

Publication number Publication date
EP1578945A2 (en) 2005-09-28
AU2003294501B2 (en) 2010-05-13
AU2003294499A1 (en) 2004-06-18
JP4646631B2 (en) 2011-03-09
WO2004048536A2 (en) 2004-06-10
WO2004048536A3 (en) 2004-08-19
JP2006507005A (en) 2006-03-02
CA2506686A1 (en) 2004-06-10
WO2004048541A2 (en) 2004-06-10
EP1578945A4 (en) 2006-09-27
WO2004048541A3 (en) 2005-08-18
AU2003294501A1 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
AU2003213606A8 (en) Mp53s as modifiers of the p53 pathway and methods of use
EP1402053A4 (en) CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1421384A4 (en) Hprp4s as modifiers of the p53 pathway and methods of use
EP1651956A4 (en) Melks as modifiers of the rac pathway and methods of use
AU2003272390A8 (en) Ampds as modifiers of the p21 pathway and methods of use
EP1535067A4 (en) PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
AU2003274911A8 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003295881A8 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003294499A8 (en) Rhebs as modifiers of the rb pathway and methods of use
AU2003251799A1 (en) Mchks as modifiers of the chk1 pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2003251826A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
EP1534852A4 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1578945A3 (en) Cct6s as modifiers of the rb pathway and methods of use
EP1587910A4 (en) Facls as modifiers of the rb pathway and methods of use
AU2003217851A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003299990A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
HK1080110A1 (en) Paks as modifiers of the chk pathway and methods of use
AU2003213665A8 (en) Lgals as modifiers of the chk pathway and methods of use
AU2003213693A8 (en) Mchks as modifiers of the chk pathway and methods of use
AU2002361654A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use
AU2003213662A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003295928A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
EP1540333A4 (en) Maxs as modifiers of the axin pathway and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase